Donate
Researchers used mouse models of pyridoxine-dependent epilepsy (PDE-ALDH7A1) to investigate why some mood-related symptoms may persist even when seizures are controlled. Their findings suggest that seizure susceptibility and certain behavioral changes may arise through different biological pathways.
PDE-ALDH7A1 is caused by changes in the ALDH7A1 gene. Seizures in PDE are often responsive to pyridoxine, or vitamin B6, but psychiatric and cognitive symptoms can persist even after seizure control. This led researchers to ask whether these symptoms are caused by the same underlying process as seizures or by a separate mechanism.
In a study published in Science Advances in July 2026, researchers created several mouse models to examine the effects of ALDH7A1 loss in different cell types. When ALDH7A1 was removed throughout the body, the mice showed both increased seizure susceptibility and changes in behaviors used to study mood and motivation.
Read the full study in Science Advances
When researchers removed ALDH7A1 specifically from liver cells, the mice showed increased seizure susceptibility without the same mood-related behavioral changes. When ALDH7A1 was removed from astrocytes in the brain, the mice showed the behavioral changes without increased seizure susceptibility.
These results suggest that different tissues may contribute to different aspects of PDE biology: liver ALDH7A1 dysfunction appeared to play a larger role in seizure susceptibility, while astrocyte ALDH7A1 dysfunction was associated with the behavioral changes studied.
Astrocytes are support cells in the brain that help regulate the environment surrounding neurons, including extracellular ions, neurotransmitters, metabolism, and neuronal excitability. The researchers found that ALDH7A1 deficiency disrupted redox homeostasis within astrocytes and was associated with reduced neuronal activity in the prelimbic cortex, a brain region involved in the behaviors being measured.
The team then tested sulforaphane (SFN), a naturally occurring compound that activates the NRF2 antioxidant pathway. In the mouse models, dietary SFN restored activity in the affected neurons and improved the mood-related behavioral measures. It did not, however, prevent the increased seizure susceptibility seen in the whole-body ALDH7A1 knockout mice.
Explore the full research findings
Why this matters
This study provides evidence that some features of PDE may not simply be downstream effects of seizures.
In these mouse models, seizure susceptibility and mood-related behavioral changes could be separated by manipulating ALDH7A1 in different tissues. This creates a new framework for studying symptoms that may persist even when seizures are well controlled and suggests that different aspects of PDE could eventually require different therapeutic strategies.
The researchers also found that restoring astrocyte-related signaling could reverse the neuronal and behavioral changes in adult mice, supporting further investigation of this pathway as a potential therapeutic target.
About sulforaphane
Sulforaphane was used in this study as a research tool to target the disrupted antioxidant pathway identified in the mice.
Although the researchers describe SFN as a promising lead compound and note that it has been studied in humans for other conditions, this study does not establish sulforaphane as a treatment for people with PDE. Additional research would be needed to determine whether targeting this pathway could be safe or beneficial in humans.
Limitations
This is a preclinical mouse study, not a clinical trial.
The mouse models do not reproduce every feature of human PDE. For example, the ALDH7A1 knockout mice used in this study did not develop spontaneous seizures under standard dietary conditions, although other research has shown that seizure susceptibility in these models can change with dietary lysine and pyridoxine levels.
There are also limitations to using mouse behavioral tests to represent complex human mood or psychiatric symptoms. The findings identify biological pathways that warrant further study, but they do not yet demonstrate that the same mechanisms or treatment effects occur in people with PDE.
Sources
Read the full research article
Safety note: This summary is educational and not medical advice. Families should speak with their medical team before making changes to medications, supplements, diet, or treatment plans.
